AI Verdict
IMMX has stronger fundamentals based on our AI analysis.
IMMX vs IMKTA Fundamental Comparison
| Metric | IMMX | IMKTA |
|---|---|---|
| Revenue | $20.0M | $1.4B |
| Net Income | $-29.4M | $28.1M |
| Net Margin | -147.2% | 2.0% |
| ROE | -31.4% | 1.7% |
| ROA | -28.1% | 1.1% |
| Current Ratio | 10.01x | 3.36x |
| Debt/Equity | 0.00x | 0.30x |
| EPS | $-0.89 | N/A |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IMMX vs IMKTA: Frequently Asked Questions
Is IMMX or IMKTA a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), IMMX has stronger fundamentals. IMMX is rated SELL (75% confidence) while IMKTA is rated SELL (72% confidence). This is not investment advice.
How does IMMX compare to IMKTA fundamentally?
Immix Biopharma, Inc. has ROE of -31.4% vs INGLES MARKETS INC's 1.7%. Net margins are -147.2% vs 2.0% respectively.
Which stock pays higher dividends, IMMX or IMKTA?
IMMX has a dividend yield of N/A or no dividend while IMKTA has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IMMX or IMKTA for long term?
For long-term investing, consider that IMMX has SELL rating with 75% confidence, while IMKTA has SELL rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IMMX vs IMKTA?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IMMX vs IMKTA, the AI consensus favors IMMX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.